Long COVID’s long R&D agenda

1d

Long COVID’s long R&D agenda

Nature Reviews Drug Discovery, Published online: 20 April 2021; doi:10.1038/d41573-021-00069-9As researchers work to understand the biology and epidemiology of post-acute COVID-19, a pioneering platform trial is now testing treatments to try to address the long-term complications of infection in previously hospitalized individuals.

1d

RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape

Nature Reviews Drug Discovery, Published online: 16 April 2021; doi:10.1038/d41573-021-00068-wPeter Horby, co-lead on the RECOVERY platform trial, discusses the origins, lessons learned and future plans for one of the most informative studies of COVID-19 therapeutics.

4d

RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape

5d

FDA new drug approvals in Q1 2021

1w

FDA new drug approvals in Q1 2021

Nature Reviews Drug Discovery, Published online: 14 April 2021; doi:10.1038/d41573-021-00067-xFDA new drug approvals in Q1 2021

1w

Blood–brain barrier-traversing biologic secures regulatory approval, in Japan

Nature Reviews Drug Discovery, Published online: 13 April 2021; doi:10.1038/d41573-021-00066-yBlood–brain barrier-traversing biologic secures regulatory approval, in Japan

1w

Blood–brain barrier-traversing biologic secures regulatory approval, in Japan

2w

Trust in Science: a novel research partnership model in Latin America

Nature Reviews Drug Discovery, Published online: 12 April 2021; doi:10.1038/d41573-021-00065-zTen years ago, GlaxoSmithKline established an innovative model for public–private research partnerships in Latin America known as Trust in Science. Here, we summarize this novel initiative, illustrate its achievements in terms of scientific advances and local...

2w

Trust in Science: a novel research partnership model in Latin America

2w